Story updated at 10 a.m. to reflect market activity.
Shares of MetLife were gaining 0.3% to $52.95 in morning trading.
The analyst firm lowered its 2014 EPS estimates for the insurance provider to $5.78 a share from $5.80 a share. Credit Suisse lowered its 2015 EPS estimates for MetLife to $5.95 a share from its previous estimates of $6.05 a share.
"All in all, MET expects the continuation of good organic growth in its international businesses excluding the impact of currency," Credit Suisse analysts wrote. "For the US, there is a more mixed picture with slow top line growth and weaker investment spreads due to low interest rates, offset by improved underwriting results. Following erosion of sales in both variable annuities and individual life insurance, MET also expects a sales recovery in both lines of business, albeit off a low base."
Must Read: Warren Buffett's 25 Favorite Stocks
Separately, TheStreet Ratings team rates METLIFE INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate METLIFE INC (MET) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins."